晚期黑色素瘤中反应适应性免疫治疗降阶梯的成本效益
该成本效益分析基于ADAPT-IT试验(随访33个月)和CheckMate 067试验(随访6.5年)数据,评估对中期影像确认肿瘤缓解的晚期黑色素瘤患者停用伊匹木单抗的成本效益。结果显示,反应适应性治疗在94.0%的情景中具成本效益,相比标准治疗每例患者节省19 891美元,增量净货币效益为28 849美元。
要点
- 反应适应性停用伊匹木单抗在94.0%的蒙特卡洛模拟情景中具成本效益。
- 相比标准治疗,反应适应性治疗每例患者估计节省19 891美元。
- 增量净货币效益为28 849美元,增量成本效益比为优势比。
核心结论
- 反应适应性治疗降阶梯可能大幅节省医疗成本,并可能成为各种资源环境下最具成本效益的策略。
- 未来试验应旨在提供非劣效性的进一步证据。
研究设计与样本
- 成本效益分析,使用ADAPT-IT试验(随访33个月)和CheckMate 067试验(随访6.5年)数据及已发表文献,分析时限为ADAPT-IT试验的33个月。
- 分析在美国背景下从美国支付方视角进行,支付意愿阈值为100 000美元/质量调整生命年(QALY)。
- 共纳入355例既往未经治疗的不可切除III期或IV期转移性黑色素瘤患者。
主要发现
- 355例患者中,41例来自ADAPT-IT试验(中位年龄65岁;28例[68%]男性),314例来自CheckMate 067试验(中位年龄61岁;206例[66%]男性)。
- 基于蒙特卡洛模拟,反应适应性治疗在94.0%的情景中为成本效益选项,增量成本效益比为优势比,增量净货币效益为28 849美元。
- 相比标准治疗,每例患者估计节省19 891美元。
- 在情景分析中,当前标准治疗仅在最佳生存假设下且支付意愿阈值超过630 000美元/QALY时才被认为具成本效益。
局限性
- 未来试验应旨在提供非劣效性的进一步证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Combination immunotherapy with nivolumab and ipilimumab has markedly improved outcomes for patients with advanced melanoma. However, these therapies pose a considerable financial burden to both patients and the health care system. The ADAPT-IT trial demonstrated comparable progression-free and overall survival for patients with response-adapted ipilimumab discontinuation compared with standard of care (SOC). OBJECTIVE: To determine the cost-effectiveness of ipilimumab discontinuation for patients with interim imaging-confirmed tumor response in the treatment of advanced melanoma. DESIGN, SETTING, AND PARTICIPANTS: This cost-effectiveness analysis was performed using data from the ADAPT-IT (follow-up of 33 months) and CheckMate 067 (follow-up of 6.5 years) trials, as well as published literature over the ADAPT-IT trial duration of 33 months. The analysis was performed in a US setting from a US-payer perspective, and the willingness-to-pay (WTP) threshold was set at $100 000/quality-adjusted life-year (QALY). A total of 355 patients with previously untreated melanoma (unresectable stage III or IV metastatic melanoma) were included. EXPOSURE: Response-adapted ipilimumab discontinuation compared with SOC therapy. MAIN OUTCOMES AND MEASURES: The primary outcomes of the CheckMate trial were overall survival and progression-free survival, while that of ADAPT-IT was objective response. This informed a decision model to estimate lifetime costs and QALYs associated with both strategies. Incremental cost, effectiveness, and cost-effectiveness ratio were assessed. Sensitivity and scenario analyses were performed to account for variability in trials and input parameters. RESULTS: Of the 355 patients included in the analysis, 41 patients were from the ADAPT-IT trial (median age, 65 years; 28 [68%] male) and 314 patients from the CheckMate 067 trial (median age, 61 years; 206 [66%] male). Response-adapted treatment was the cost-effective option in 94.0% of scenarios based on Monte Carlo simulations, with a dominant incremental cost-effectiveness ratio and an incremental net monetary benefit of $28 849 compared with SOC therapy. Cost savings were estimated at $19 891 per patient compared with SOC. In scenario analyses, current SOC was only considered as a cost-effective option under best survival assumptions and if the willingness-to-pay threshold exceeded $630 000/QALY. CONCLUSIONS AND RELEVANCE: This economic evaluation demonstrated that response-adapted treatment de-escalation in patients with advanced melanoma may lead to considerable savings in health care costs and could represent the most cost-effective strategy across various resource settings. Future trials should aim to provide further evidence on noninferiority.
引用
- Cartun Z, Kunz WG, Heinzerling L, et al. Cost-effectiveness of Response-Adapted De-escalation of Immunotherapy in Advanced Melanoma. JAMA Dermatol. 2022. PMID: 36260321. doi:10.1001/jamadermatol.2022.4556
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。